Takekita, Yoshiteru
Hiraoka, Shuichi
Iwama, Yasuhiro
Matsui, Daisuke
Aoki, Nobuatsu
Ogata, Haruhiko
Funatsuki, Toshiya
Shimizu, Toshiyuki
Murase, Yuji
Shimamoto, Yutaro
Koshikawa, Yosuke
Kato, Masaki
Article History
Received: 2 April 2024
Accepted: 29 July 2024
First Online: 2 August 2024
Declarations
:
: This study was approved by the institutional review board, and written informed consent was waived because of the retrospective design.
: Not applicable.
: YT has received grant funding from the Japan Society for the Promotion of Science and speaker’s honoraria from Meiji-Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical, Otsuka, Eisai, MSD K.K. Daiichi-Sankyo, Pfizer, UCB Japan, and Takeda Pharmaceutical. NA received speaker honoraria from Daiichi-Sankyo, Eli Lilly, Meiji-Seika Pharma, Janssen Pharmaceutical, Eisai, and Otsuka. TF has received grant funding from the Japan Society for the Promotion of Science and speaker’s honoraria from Sumitomo Pharma, Otsuka, Meiji Seika Pharma, Janssen Pharmaceutical, Takeda Pharmaceutical, Lundbeck, Viatris Inc, Eisai, Mochida Pharmaceutical. TS has received speaker’s honoraria from Meiji-Seika Pharma, Sumitomo Pharma, Janssen Pharmaceutical, and Mochida Pharmaceutical. YM received speaker honoraria from Sumitomo Pharma, Meiji-Seika Pharma, Takeda Pharmaceutical, Lundbeck, and Viatris Inc. YK has received speaker’s honoraria, and consulting fees from Takeda Pharmaceutical Co., Ltd. MK has received grant funding from AMED, the Japanese Ministry of Health, Labour and Welfare, the Japan Society for the Promotion of Science, SENSHIN Medical Research Foundation, the Japan Research Foundation for Clinical Pharmacology, and the Japanese Society of Clinical Neuropsychopharmacology, and consulting fees from Sumitomo Pharma Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Lundbeck Japan K.K., Takeda Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Sumitomo Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Janssen Pharmaceutical K.K., Shionogi & Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Lundbeck Japan K.K., Viatris Inc., Eisai Co., Ltd., Kyowa Pharmaceutical Industry Co., Ltd., Ono Pharmaceutical Co., Ltd. HO and YS declares no conflict of interest associated with this manuscript. SH, YI and DM are full-time employees of Meiji Seika Pharma Co. Ltd.